Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ATM |
| Variant | R2227C |
| Impact List | missense |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | ATM R2227C lies within the FAT domain of the Atm protein (UniProt.org). R2227C results in reduced Atm protein expression, loss of Atm autophosphorylation and Smc1 phosphorylation, and intermediate radiosensitivity of cultured cells (PMID: 18634022), and therefore, is predicted to lead to a loss of Atm protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
ATM mutant ATM inact mut ATM R2227C |
| Transcript | NM_000051.4 |
| gDNA | chr11:g.108325416C>T |
| cDNA | c.6679C>T |
| Protein | p.R2227C |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001351834.2 | chr11:g.108325416C>T | c.6679C>T | p.R2227C | RefSeq | GRCh38/hg38 |
| XM_011542840.4 | chr11:g.108325416C>T | c.6679C>T | p.R2227C | RefSeq | GRCh38/hg38 |
| XM_005271562.6 | chr11:g.108325416C>T | c.6679C>T | p.R2227C | RefSeq | GRCh38/hg38 |
| XM_006718843.5 | chr11:g.108325416C>T | c.6679C>T | p.R2227C | RefSeq | GRCh38/hg38 |
| XM_047426975.1 | chr11:g.108325416C>T | c.6679C>T | p.R2227C | RefSeq | GRCh38/hg38 |
| XM_047426976.1 | chr11:g.108325416C>T | c.6679C>T | p.R2227C | RefSeq | GRCh38/hg38 |
| NM_000051.4 | chr11:g.108325416C>T | c.6679C>T | p.R2227C | RefSeq | GRCh38/hg38 |
| XM_011542843.3 | chr11:g.108325416C>T | c.6679C>T | p.R2227C | RefSeq | GRCh38/hg38 |
| XM_017017790.3 | chr11:g.108325416C>T | c.6679C>T | p.R2227C | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM R2227C | prostate cancer | sensitive | Olaparib | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (PROfound) that supported FDA approval, Lynparza (olaparib) improved progression-free survival (7.4 vs 3.6 mo, HR 0.34, p<0.001), objective response rate (33% vs 2%, OR 20.86, p<0.001), and median overall survival (18.5 vs 15.1 mo, HR 0.64, p=0.02) over control in metastatic prostate cancer patients harboring inactivating BRCA/ATM mutations as detected by approved assays, including ATM R2227C, HR was 1.04 in ATM-mutant group (PMID: 32343890; NCT02987543). | detail... 32343890 detail... |